症状性外周动脉疾病血运重建患者他汀与抗血小板治疗不足的危险因素
基于纽约大血管研究组(VSGGNY)2011-2013年数据库,分析1,030例因症状性外周动脉疾病(PAD)行下肢旁路术或外周血管介入的患者。术前他汀使用率59%,抗血小板治疗率79%。无高血压或冠心病等心血管病史的患者他汀使用率显著更低,提示这类患者医疗管理存在改进空间。
要点
- 症状性PAD血运重建患者术前他汀使用率仅59%,抗血小板治疗率79%。
- 无高血压或冠心病等心血管危险因素的患者他汀使用率显著更低。
核心结论
- 无心血管病史的症状性PAD患者术前接受他汀和抗血小板治疗的可能性更低,存在医疗改进机会。
研究设计与样本
- 回顾性队列研究,使用VSGGNY数据库纳入2011-2013年因症状性PAD行外周血管介入(n=822,80%)或下肢旁路术(n=208,20%)的1,030例患者。
主要发现
- 总体术前他汀使用率59%,抗血小板治疗率79%。
- 无高血压患者他汀使用率39.3%,有高血压者63%(P<0.0001)。
- 无冠心病(CAD)或既往CABG/PCI者他汀使用率47.4%,有CAD或既往CABG/PCI者75.2%(P<0.0001)。
关键数值与推荐
- 他汀使用率:高血压者63% vs 无高血压者39.3%(P<0.0001);CAD伴既往CABG/PCI者75.2% vs 无CAD者47.4%(P<0.0001)。
临床怎么用
- 对无高血压或冠心病等传统心血管危险因素的症状性PAD患者,应主动评估并优化他汀和抗血小板治疗。
- 高龄(>80岁)患者他汀使用可能不足,需关注这一人群的医疗管理。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this study was to identify risk factors for suboptimal medical therapy (defined as reported antiplatelet and statin use) among patients undergoing lower extremity bypass (LEB) and peripheral vascular interventions (PVIs) for symptomatic peripheral arterial disease (PAD). METHODS: The Vascular Study Group of Greater New York (VSGGNY) database was used to identify all patients undergoing PVI or LEB for PAD (2011-2013). Bivariate analyses were performed to identify characteristics of patients who were not prescribed statins and/or antiplatelet agents before revascularization. Multivariate relative risk regression models were developed to identify patients at risk for suboptimal therapy, with regards to antiplatelet and statin therapy. RESULTS: About 1,030 patients underwent endovascular therapy (n = 822; 80%) or surgical bypass (n = 208; 20%) for symptomatic PAD (57.2% claudication; 15% rest pain and 27.8% tissue loss). Overall, preoperative statin use was observed in 59%. Preoperative antiplatelet therapy was observed in 79% of patients. Bivariate analysis revealed comparatively reduced statin use among patients without other cardiovascular risk factors including hypertension (63% vs. 39.3%; P < 0.0001) and coronary artery disease (CAD) with or without prior cardiac revascularization (coronary artery bypass grafting [CABG]/percutaneous coronary intervention [PCI]; 75.2% vs. 47.4%; P < 0.0001). Multivariate relative risk regression confirmed higher rates of statin use among patients with other cardiovascular risk factors including hypertension (1.14 [1.02-1.27]; P = 0.02) and CAD with prior CABG/PCI (1.22 [1.13-1.31]; P < 0.0001). Reduced statin use was observed in patients over 80 years old. (0.92 [0.84-0.1.0]; P = 0.059). By multivariate regression, antiplatelet therapy use was associated with CAD and/or prior CABG/PCI (1.11 [1.04-1.17]; P = 0.0015) and prior peripheral revascularization (1.07 [1.01-1.13]; P = 0.03). CONCLUSIONS: Patients with symptomatic PAD, but without an antecedent cardiovascular history, are less likely to be optimally managed with statins and antiplatelet therapy preoperatively. Given the established role of these medications in the optimal medical management of patients with PAD, this presents an opportunity for improvement in the overall vascular care of patients undergoing intervention for symptomatic PAD at VSGGNY centers.
引用
- Meltzer AJ, Sedrakyan A, Connolly PH, et al. Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2017. PMID: 28602895. doi:10.1016/j.avsg.2017.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。